Literature DB >> 18593938

Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress.

Penny E Lovat1, Marco Corazzari, Jane L Armstrong, Shaun Martin, Vittoria Pagliarini, David Hill, Anna M Brown, Mauro Piacentini, Mark A Birch-Machin, Christopher P F Redfern.   

Abstract

Exploiting vulnerabilities in the intracellular signaling pathways of tumor cells is a key strategy for the development of new drugs. The activation of cellular stress responses mediated by the endoplasmic reticulum (ER) allows cancer cells to survive outside their normal environment. Many proteins that protect cells against ER stress are active as protein disulfide isomerases (PDI) and the aim of this study was to test the hypothesis that apoptosis in response to ER stress can be increased by inhibiting PDI activity. We show that the novel chemotherapeutic drugs fenretinide and velcade induce ER stress-mediated apoptosis in melanoma cells. Both stress response and apoptosis were enhanced by the PDI inhibitor bacitracin. Overexpression of the main cellular PDI, procollagen-proline, 2-oxoglutarate-4-dioxygenase beta subunit (P4HB), resulted in increased PDI activity and abrogated the apoptosis-enhancing effect of bacitracin. In contrast, overexpression of a mutant P4HB lacking PDI activity did not increase cellular PDI activity or block the effects of bacitracin. These results show that inhibition of PDI activity increases apoptosis in response to agents which induce ER stress and suggest that the development of potent, small-molecule PDI inhibitors has significant potential as a powerful tool for enhancing the efficacy of chemotherapy in melanoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18593938      PMCID: PMC2917766          DOI: 10.1158/0008-5472.CAN-08-0035

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

Review 1.  ER stress and the unfolded protein response.

Authors:  Martin Schröder; Randal J Kaufman
Journal:  Mutat Res       Date:  2005-01-06       Impact factor: 2.433

Review 2.  Cutaneous melanoma.

Authors:  John F Thompson; Richard A Scolyer; Richard F Kefford
Journal:  Lancet       Date:  2005 Feb 19-25       Impact factor: 79.321

3.  Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.

Authors:  Malihe Eskandarpour; Shahryar Kiaii; Chaoyong Zhu; Juan Castro; Andrew J Sakko; Johan Hansson
Journal:  Int J Cancer       Date:  2005-05-20       Impact factor: 7.396

Review 4.  The role of B-RAF in melanoma.

Authors:  Vanessa C Gray-Schopfer; Silvy da Rocha Dias; Richard Marais
Journal:  Cancer Metastasis Rev       Date:  2005-01       Impact factor: 9.264

5.  Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.

Authors:  Yolanda Fernández; Monique Verhaegen; Thomas P Miller; Jenny L Rush; Philipp Steiner; Anthony W Opipari; Scott W Lowe; María S Soengas
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

6.  Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases.

Authors:  Franco Carta; Pietro P Demuro; Cristina Zanini; Antonella Santona; Daniele Castiglia; Stefania D'Atri; Paolo A Ascierto; Maria Napolitano; Antonio Cossu; Bruna Tadolini; Franco Turrini; Antonella Manca; Maria C Sini; Giuseppe Palmieri; And Carla Rozzo
Journal:  Melanoma Res       Date:  2005-08       Impact factor: 3.599

7.  The selective inhibition of beta 1 and beta 7 integrin-mediated lymphocyte adhesion by bacitracin.

Authors:  Y Mou; H Ni; J A Wilkins
Journal:  J Immunol       Date:  1998-12-01       Impact factor: 5.422

8.  Rapid mass spectrometric peptide sequencing and mass matching for characterization of human melanoma proteins isolated by two-dimensional PAGE.

Authors:  K R Clauser; S C Hall; D M Smith; J W Webb; L E Andrews; H M Tran; L B Epstein; A L Burlingame
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

9.  The role of the thiol/disulfide centers and peptide binding site in the chaperone and anti-chaperone activities of protein disulfide isomerase.

Authors:  A Puig; M M Lyles; R Noiva; H F Gilbert
Journal:  J Biol Chem       Date:  1994-07-22       Impact factor: 5.157

10.  Up-regulation of p21WAF1 by phorbol ester and calcium in human keratinocytes through a protein kinase C-dependent pathway.

Authors:  C Todd; N J Reynolds
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

View more
  75 in total

1.  Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma.

Authors:  M Corazzari; F Rapino; F Ciccosanti; P Giglio; M Antonioli; B Conti; G M Fimia; P E Lovat; M Piacentini
Journal:  Cell Death Differ       Date:  2014-11-07       Impact factor: 15.828

Review 2.  The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?

Authors:  Martin McLaughlin; Koen Vandenbroeck
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

3.  ERp57 as a novel cellular factor controlling prion protein biosynthesis: Therapeutic potential of protein disulfide isomerases.

Authors:  Martin Sepulveda; Pablo Rozas; Claudio Hetz; Danilo B Medinas
Journal:  Prion       Date:  2016       Impact factor: 3.931

Review 4.  Targeting the unfolded protein response in disease.

Authors:  Claudio Hetz; Eric Chevet; Heather P Harding
Journal:  Nat Rev Drug Discov       Date:  2013-09       Impact factor: 84.694

5.  Dose-dependent proteomic analysis of glioblastoma cancer stem cells upon treatment with γ-secretase inhibitor.

Authors:  Lan Dai; Jintang He; Yashu Liu; Jaeman Byun; Anuradha Vivekanandan; Subramaniam Pennathur; Xing Fan; David M Lubman
Journal:  Proteomics       Date:  2011-10-24       Impact factor: 3.984

6.  Small molecule-induced oxidation of protein disulfide isomerase is neuroprotective.

Authors:  Anna Kaplan; Michael M Gaschler; Denise E Dunn; Ryan Colligan; Lewis M Brown; Arthur G Palmer; Donald C Lo; Brent R Stockwell
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

Review 7.  Induction of endoplasmic reticulum stress as a strategy for melanoma therapy: is there a future?

Authors:  David S Hill; Penny E Lovat; Nikolas K Haass
Journal:  Melanoma Manag       Date:  2014-12-04

8.  Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.

Authors:  Stella Sun; Derek Lee; Amy S W Ho; Jenny K S Pu; X Q Zhang; Nikki P Lee; Philip J R Day; W M Lui; C F Fung; Gilberto K K Leung
Journal:  Neuro Oncol       Date:  2013-02-26       Impact factor: 12.300

9.  Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.

Authors:  Girija Dasmahapatra; Dmitry Lembersky; Mohamed Rahmani; Lora Kramer; Jonathan Friedberg; Richard I Fisher; Paul Dent; Steven Grant
Journal:  Cancer Biol Ther       Date:  2009-05-08       Impact factor: 4.742

10.  NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma.

Authors:  R J Flockhart; J L Armstrong; N J Reynolds; P E Lovat
Journal:  Br J Cancer       Date:  2009-09-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.